May 2021

This summary highlights how cells for TIL therapy are generated, considerations for TIL therapy and, the utility of co-administration of TIL therapy with other cancer immunotherapies. The two main protocols for TIL production are conventional...

Professor Soraya Zorro began her lecture with an overview of TILs and TILs therapy. TILs are lymphocyte populations that migrate to and infiltrate the tumour. These lymphocytes recognise specific antigens, elicit direct and indirect cytotoxic activity.

This article highlights lecture proceeding by Professor Augusto Ochoa which focused on: (i) characteristics, (ii) physiologic functions, (iii)  role in tumour progression and metastasis, (iv) and the potential as therapeutic targets of MDSCs.

In this article, we highlight lecture proceedings by Professor Vasquez at the IUIS-ALACI-ACAAI Immuno-Colombia 2021 course, where she discussed how monoclonal antibodies used for anti-cytokine therapies are developed and other strategies for blocking...

This article highlights a lecture by clinician-scientist Professor Vasquez at the IUIS-ALACI-ACAAI Immuno-Colombia 2021 course. During her lecture, she discussed anti-cytokine therapy as a way to manage many autoimmune and inflammatory diseases.

Today, we highlight part 2 of a lecture by Professor Queckenbush at the IUIS-ALACI-ACAAI Immuno-Colombia 2021 course. During her lecture she presented a case study that highlights an exceptional responder to immune checkpoint inhibitors.

This summary highlights a lecture presented during the IUIS-ALACI-ACAAI Immuno-Colombia 2021 course-themed "Mechanisms and Approaches to Immunotherapy for Cancer and Chronic Inflammatory Diseases”. Today, we highlight a talk focused on Checkpoint Blockade-based Therapies.

Recent study reports that COVID-19 severity and mortality in Kazakhstan were associated with older age, comorbidities, increased leukocyte counts, and male sex. The SARS-CoV-2 diversity, involving a lineage unique to Kazakhstan...

A Recent study demonstrates the role of the C5a-C5aR1 axis in the promoting immunopathology associated with cobra venom. These findings have potential implications for the development of novel snake bite immunotherapy.

Studies suggest that a single dose of BNT162b2 confers the same benefit as two doses given to those with or without previous SARS-CoV-2 infection; this may be crucial for vaccine distribution programs as a single shot could be sufficient in previously infected people.